Content
All Posts > Content under Pharma/Biotech
7 Monster Stock Market Predictions For The Week Of February 23
Article By:
Michael J. Kramer
Read
Sunday, February 23, 2020 12:37 PM EDT
It will not be a busy week in-terms of economic news low, but we will likely see a great amount of volatility. Markets will still be trying to figure out what the potential impact of the coronavirus is on the economy.
Weighing The Week Ahead: Investors Can Always Learn Something From Mr. Buffett
Article By:
Jeff Miller
Read
Sunday, February 23, 2020 10:42 AM EDT
We have a big economic calendar this week including important data on consumer confidence, personal income and spending, and inflation. The punditry will be asking: What does Warren think?
Week In Review: CANbridge Raises $98 Million For In-licensed Orphan Disease And Targeted Cancer Candidates
Article By:
ChinaBio® Today
Read
Sunday, February 23, 2020 12:00 AM EDT
CANbridge Pharma, a Beijing biopharma developing products for orphan diseases and targeted cancers, closed a $98 million Series D financing led by General Atlantic and WuXi AppTec. The two companies has the option to invest additional $10 million.
Market Briefing For Thursday, February 20
Article By:
Gene Inger
Read
Thursday, February 20, 2020 3:54 AM EDT
Persistent 'top-heavy' dominance - of the S&P continues churning-out higher highs, irrespective of growth downgrades anticipated, while some other stocks, with actual growth potential, languish relatively.
Healthcare (Top 30 Weights) Earnings Estimates And Revisions
Article By:
T.J. Hayes
Read
Monday, February 17, 2020 5:44 AM EDT
The cumulative 2020 earnings power of these 30 stocks was revised down by -.34% in the past 60 days.
In this article: EW, HCA, HUM, JNJ, LLY, MDT, MRK, PFE, SYK, TMO, UNH, ILMN, AMGN, BIIB, GILD, ISRG, VRTX Also: ABT, AGN, BAX, BDX, BMY, BSX, CI, CNC, CVS, DHR, XLV, ZTS, ABBV, ANTM
Paulson Adds Pretium, Exits United Tech In Q4
Article By:
The Fly
Read
Sunday, February 16, 2020 12:29 PM EDT
John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of December 31, 2019. The fund's top holdings as of December 31, in order of size, were Bausch Health, SPDR Gold Shares, Allergan, Discovery Class C and Horizon Therapeutics
In this article: AGN, CPE, PCG, QEP, S, TIF, UTX, LOGM, DISCK, GOLD, HZNP, TECD, GLD, PVG, CZR, BHC, NMRK, INSW, LYFT
Alkermes Targets Bipolar Disorder And Schizophrenia
Article By:
MoneyShow.com
Read
Sunday, February 16, 2020 11:52 AM EDT
We strongly recommend that investors take advantage of the weakness and buy Alkermes, whose treatment of schizophrenia and bipolar disorder has been accepted by the FDA for review.
Week In Review: Bio-Thera Raises $241 Million In Shanghai STAR IPO For Antibody Portfolio
Article By:
ChinaBio® Today
Read
Saturday, February 15, 2020 4:19 PM EDT
Bio-Thera Solutions of Guangzhou priced its IPO on Shanghai’s STAR Board to raise $241 million at a valuation of almost $2 billion. The offering, which placed 60 million shares at RMB32.76 each, was reported to be 3,225 times oversubscribed.
Aptose Biosciences - Chart Of The Day
Article By:
Jim Van Meerten
Read
Friday, February 14, 2020 2:43 PM EDT
Aptose Biosciences Inc. is a clinical-stage biotechnology company.
Canopy Growth Reports Very Positive Q3 Results - Stock Jumps
Article By:
Lorimer Wilson
Read
Friday, February 14, 2020 12:35 PM EDT
Canopy Growth Corporation today announced its financial results for the third quarter ended December 31, 2019, and stock jumps.
Aurora Cannabis Q2 2020 Results Show Declines Across The Board
Article By:
Lorimer Wilson
Read
Thursday, February 13, 2020 7:00 AM EDT
Aurora reiterates its outlook for Q3 that cannabis revenue will be impacted by industry headwinds, and as such will likely show modest to no growth relative to fiscal Q2's cannabis revenue.
In this article: ACB
